Brain Metastases in Hematologic Malignancies

  • Nancy D. Doolittle
Part of the Cancer Treatment and Research book series (CTAR, volume 136)


Central nervous system (CNS) involvement in patients with hematologic malignancies is a challenging clinical problem which carries a poor prognosis [1–5]. Hematopoietic and lymphoid neoplasms involve the CNS with varying frequencies. For example, long term disease control in childhood acute lymphoblastic leukemia (ALL) was rare before the recognition of occult CNS disease at diagnosis [6, 7]. Patient outcomes and cure rates dramatically improved once adequate prophylaxis against CNS disease was instituted in the 1970’s, as part of standard treatment for childhood ALL [6–8].


Brain Metastasis Acute Lymphoblastic Leukemia Primary Central Nervous System Lymphoma Central Nervous System Disease Central Nervous System Involvement 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    van Besien K, Ha CS, Murphy S et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 1998; 91:1178–1184.PubMedGoogle Scholar
  2. 2.
    Bierman P, Giglio P. Diagnosis and treatment of central nervous system involvement in non-Hodgkin’s lymphoma. Hematol Oncol Clin N Am 2005; 19:597–609.CrossRefGoogle Scholar
  3. 3.
    Lister TA, Coiffier B, Armitage JO. Non-Hodgkin’s lymphoma. In Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, editors. Clinical oncology. Philadelphia: Elsevier, 2004:3015–3076.Google Scholar
  4. 4.
    Montoto S, Lister TA. Secondary central nervous system lymphoma: risk factors and prophylaxis. Hematol Oncol Clin N Am 2005; 19:751–763.CrossRefGoogle Scholar
  5. 5.
    Grier J, Batchelor T. Metastatic neurologic complications of non-Hodgkin’s lymphoma. Curr Oncol Rep 2005; 7:55–60.CrossRefPubMedGoogle Scholar
  6. 6.
    Steinherz PG. CNS leukemia: problem of diagnosis, treatment, and outcome. J Clin Oncol 1995; 13:310–313.PubMedGoogle Scholar
  7. 7.
    Pinkel D, Woo S. Prevention and treatment of meningeal leukemia in children. Blood 1994; 84:355–366.PubMedGoogle Scholar
  8. 8.
    Bunn PA, Schein PS, Banks PM et al. Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited. Blood 1976; 47:3–10.PubMedGoogle Scholar
  9. 9.
    Kantarjian HM, Faderl S. Acute lymphoid leukemia in adults. In Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, editors. Clinical oncology. Philadelphia:Elsevier, 2004:2793–2824.Google Scholar
  10. 10.
    Stewart DJ, Keating MJ, McCredie KB et al. Natural history of central nervous system acute leukemia in adults. Cancer 1981; 47:184–196.CrossRefPubMedGoogle Scholar
  11. 11.
    Hegde U, Filie A, Little RF et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 2005; 105:496–502.CrossRefPubMedGoogle Scholar
  12. 12.
    Kesari S, Batchelor TT. Leptomeningeal metastases. Neurol Clin N Am 2003; 21:25–66.Google Scholar
  13. 13.
    Sheehan T, Cuthbert RJG, Parker AC. Central nervous system involvement in haematological malignancies. Clin Lab Haemat 1989; 11:331–338.CrossRefGoogle Scholar
  14. 14.
    Abbott NJ, Romero IA. Transporting therapeutics across the blood-brain barrier. Mol Med Today 1996; 2:106–113.CrossRefPubMedGoogle Scholar
  15. 15.
    Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 1998; 42:1083–1100.CrossRefPubMedGoogle Scholar
  16. 16.
    Leis JF, Stepan DE, Curtin PT et al. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma 2004; 45:695–698.CrossRefPubMedGoogle Scholar
  17. 17.
    Petzer AL, Gunsilius E, Hayes M et al. Low concentrations of STI571 in the cerebrospinal fluid: a case report. Br J Haematol 2002; 117:623–625.CrossRefPubMedGoogle Scholar
  18. 18.
    Takayama N, Sato N, O’Brien SG et al. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukemia due to poor penetration into cerebrospinal fluid. Br J Hematol 2002; 119:106–108.CrossRefGoogle Scholar
  19. 19.
    Traweek ST. Nervous system involvement by lymphoma, leukemia and other hematopoietic cell proliferations. In Bigner DD, McLendon RE, Bruner JM, editors. Russell and Rubinstein’s pathology of tumors of the nervous system. London: Oxford University Press, 1998:195–237.Google Scholar
  20. 20.
    Ahn JY, Kwon SO, Shin MS et al. Meningeal chloroma (granulocytic sarcoma) in acute lymphoblastic leukemia mimicking a falx meningioma. J Neurooncol 2002; 60:31–35.CrossRefPubMedGoogle Scholar
  21. 21.
    Lee S-H, Park J, Hwang S-K. Isolated recurrence of intracerebral granulocytic sarcoma in acute lymphoblastic leukemia: a case report. J Neurooncol 2006; 80:101–104.CrossRefPubMedGoogle Scholar
  22. 22.
    Neiman RS, Barcos M, Berard C et al. Granulocytic sarcoma: a clinicopathologic study of 61 biopsied cases. Cancer 1981; 48:1426–1437.CrossRefPubMedGoogle Scholar
  23. 23.
    Jaffe ES. The World Health Organization classification of hematologic malignancies. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, editors. Clinical oncology. Philadelphia: Elsevier, 2004: 2723–2730.Google Scholar
  24. 24.
    Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361–1392.PubMedGoogle Scholar
  25. 25.
    Jaffe ES, Harris NL, Stein H et al. Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2001.Google Scholar
  26. 26.
    Sehn LH, Berry B, Chhanabhai M et al. Revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood e-pub Nov. 14, 2006; doi 10.1182/blood-2006–08–038257.Google Scholar
  27. 27.
    Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002; 346:235–242.CrossRefPubMedGoogle Scholar
  28. 28.
    Feugier P, Van Hoof A, Sebban C et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study of the Group d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005; 23:4117–4126.CrossRefPubMedGoogle Scholar
  29. 29.
    Sehn LH, Donaldson J, Chhanabhai M et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23:5027–5033.CrossRefPubMedGoogle Scholar
  30. 30.
    Harjunpaa A, Wiklund T, Collan et al. Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk Lymphoma 2001; 42:731–738.CrossRefPubMedGoogle Scholar
  31. 31.
    Feugier P, Virion JM, Tilly H et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 2004; 15:129–133.CrossRefPubMedGoogle Scholar
  32. 32.
    Rubenstein JL, Combs D, Rosenberg J et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003; 101: 466–468.CrossRefPubMedGoogle Scholar
  33. 33.
    Bollen ELEM, Brouwer RE, Hamers S et al. Central nervous system relapse in non-Hodgkin lymphoma: a single-center study of 532 patients. Arch Neurol 1997; 54:854–859.PubMedGoogle Scholar
  34. 34.
    Ersboll J, Schultz HB, Thomsen BLR et al. Meningeal involvement in non-Hodgkin’s lymphoma: symptoms, incidence, risk factors and treatment. Scand J Haematol 1985; 35:487–496.PubMedCrossRefGoogle Scholar
  35. 35.
    Hollender A, Kvaloy S, Nome O et al. Central nervous system involvement following diagnosis of non-Hodgkin’s lymphoma: a risk model. Ann Oncol 2002; 13:1099–1107.CrossRefPubMedGoogle Scholar
  36. 36.
    Batchelor T, Leahy N, Kaufman D. High-dose methotrexate for isolated central nervous system relapse in patients with testicular non-Hodgkin’s lymphoma. Clin Lymphoma 2001; 2:116–119.CrossRefPubMedGoogle Scholar
  37. 37.
    Montserrat E, Bosch F, Lopez-Guillermo A et al. CNS involvement in mantle-cell lymphoma. J Clin Oncol 1996; 14:941–944.PubMedGoogle Scholar
  38. 38.
    Zucca E, Conconi A, Mughal TI et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the international extranodal lymphoma study group. J Clin Oncol 2003; 21:20–27.CrossRefPubMedGoogle Scholar
  39. 39.
    Spectre G, Gural A, Amir G et al. Central nervous system involvement in indolent lymphomas. Ann Oncol 2005; 16:450–454.CrossRefPubMedGoogle Scholar
  40. 40.
    Zinzani PL, Magagnoli M, Frezza G et al. Isolated central nervous system relapse in aggressive non-Hodgkin’s lymphoma: the Bologna experience. Leuk Lymphoma 1999; 32:571–576.PubMedGoogle Scholar
  41. 41.
    Bokstein F, Lossos A, Lossos IS et al. Central nervous system relapse of systemic non-Hodgkin’s Lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy. Leuk Lymphoma 2002; 43:587–593.CrossRefPubMedGoogle Scholar
  42. 42.
    Haioun C, Besson C, Lepage E et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin’s lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patients. Ann Oncol 2000; 11:685–690.CrossRefPubMedGoogle Scholar
  43. 43.
    Keldsen N, Michalski W, Bentzen SM et al. Risk factors for central nervous system involvement in non-Hodgkin’s lymphoma. Acta Oncol 1996; 35: 703–708.CrossRefPubMedGoogle Scholar
  44. 44.
    Bashir RM, Bierman PJ, Vose JM et al. Central nervous system involvement in patients with diffuse aggressive non-Hodgkin’s lymphoma. Am J Clin Oncol 1991; 14:478–482.CrossRefPubMedGoogle Scholar
  45. 45.
    Jahnke K, Thiel E, Martus P et al. Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system. Ann Hematol 2006; 85:45–50.CrossRefPubMedGoogle Scholar
  46. 46.
    Boehme V, Zeynalova S, Kloess M et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma: a survey of 1693 patients treated in protocols of the German high-grade non-Hodgkin’s lymphoma study group (DSHNHL). Ann Oncol, e-pub October 3, 2006, doi:10.1093/annonc/mdl327.Google Scholar
  47. 47.
    Cairncross JG, Posner JB. Neurological complications of malignant lymphoma. In: Vinken PJ, Bruyn GW, editors. Handbook of clinical neurology. Amsterdam: Elsevier North-Holland Biomedical Press, 1980:27–61.Google Scholar
  48. 48.
    Hoster HA, Dratman MB, Craver LF et al. Hodgkin’s disease, 1832–1947. Cancer Res 1948; 8:1–78.PubMedGoogle Scholar
  49. 49.
    Recht L, Mrugala M. Neurologic complications of hematologic neoplasms. Neurol Clin N Am 2003; 21:87–105.Google Scholar
  50. 50.
    Buckstein R, Lim W, Franssen E et al. CNS prophylaxis and treatment in non-Hodgkin’s lymphoma: variation in practice and lessons from the literature. Leuk Lymphoma 2003; 44:955–962.CrossRefPubMedGoogle Scholar
  51. 51.
    Tomita N, Kodama F, Kanamori H et al. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-Hodgkin’s lymphoma. Cancer 2002; 95:576–580.CrossRefPubMedGoogle Scholar
  52. 52.
    Levitt LJ, Dawson DM, Rosenthal DS et al. CNS involvement in the non-Hodgkin’s lymphomas. Cancer 1980; 45:545–552.CrossRefPubMedGoogle Scholar
  53. 53.
    Litam JP, Cabanillas F, Smith TL et al. Central nervous system relapse in malignant lymphomas: risk factors and implications for prophylaxis. Blood 1979; 54:1249–1257.PubMedGoogle Scholar
  54. 54.
    Chamberlain MC. Leptomeningeal metastases: a review of evaluation and treatment. J Neurooncol 1998; 37:271–284.CrossRefPubMedGoogle Scholar
  55. 55.
    Siegal T. Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of intra-CSF chemotherapy? J Neurooncol 1998; 38: 151–157.CrossRefPubMedGoogle Scholar
  56. 56.
    Recht L, Straus DJ, Cirrincione C et al. Central nervous system metastases from Non-Hodgkin’s lymphoma: treatment antd prophylaxis. Am J Med 1988; 84:425–435.CrossRefPubMedGoogle Scholar
  57. 57.
    Mackintosh FR, Colby TV, Podolsky WJ et al. Central nervous system involvement in non-Hodgkin’s Lymphoma: an analysis of 105 cases. Cancer 1982; 49:586–595.CrossRefPubMedGoogle Scholar
  58. 58.
    Doolittle ND, Abrey L, Shenkier T et al. Isolated brain parenchyma relapse of non-Hodgkin’s Lymphoma: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG). Blood 2006; 108:574a (abstract #2026).Google Scholar
  59. 59.
    Wong ET, Portlock CS, O’Brien JP et al. Chemosensitive epidural spinal cord disease in non-Hodgkin’s lymphoma. Neurology 1996; 46:1543–1547.PubMedGoogle Scholar
  60. 60.
    van Oostenbrugge RJ, Twijnstra A. Presenting features and value of diagnostic procedures in leptomeningeal metastases. Neurology 1999; 53:382–385.PubMedGoogle Scholar
  61. 61.
    DeAngelis LM, Cairncross JG. A better way to find tumor in the CSF? Neurology 2002; 58:339–340.PubMedGoogle Scholar
  62. 62.
    Ferreri AJM, Abrey LE, Blay J-V et al. Summary statement on primary central nervous system lymphomas from the eighth international conference on malignant lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol 2003; 21:2407–2414.CrossRefPubMedGoogle Scholar
  63. 63.
    Tomita N, Kodama F, Kanamori H et al. Secondary central nervous system lymphoma. Int J Hematol 2006; 84:128–135.CrossRefPubMedGoogle Scholar
  64. 64.
    Colocci N, Glantz M, Recht L. Prevention and treatment of central nervous system involvement by non-Hodgkin’s lymphoma: a review of the literature. Semin Neurol 2004; 24:395–404.CrossRefPubMedGoogle Scholar
  65. 65.
    Gavrilovic IT, Hormigo A, Yahalom J et al. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 2006; 24: 4570–4574.CrossRefPubMedGoogle Scholar
  66. 66.
    Glantz MJ, Cole BF, Recht L et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: Is intrathecal chemotherapy necessary? J Clin Oncol 1998; 16:1561–1567.PubMedGoogle Scholar
  67. 67.
    Bleyer WA. Neurologic sequelae of methotrexate and ionizing radiation: a new classification. Cancer Treatment Reports 1981; 65(Suppl 1):89–98.PubMedGoogle Scholar
  68. 68.
    Young RC, Howser DM, Anderson T et al. Central nervous system complications of non-Hodgkin’s Lymphoma. Am J Med 1979; 66:435–443.CrossRefPubMedGoogle Scholar
  69. 69.
    Kasaman YL, Jones RJ, Piantadosi S et al. High-dose chemotherapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement. Biol Blood Marrow Transplant 2005; 11:93–100.CrossRefGoogle Scholar
  70. 70.
    van Besien K, Forman A, Champlin R. Central nervous system relapse of lymphoid malignancies in adults: the role of high-dose chemotherapy. Ann Oncol 1997; 8:515–524.CrossRefPubMedGoogle Scholar
  71. 71.
    Williams CD, Pearce R, Taghipour G et al. Autologous bone marrow transplantation for patients with non-Hodgkin’s lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome: a report by the European Bone Marrow Transplant Lymphoma Registry. J Clin Oncol 1994; 12: 2415–2422.PubMedGoogle Scholar
  72. 72.
    van Besien K, Przepiorka D, Mehra R et al. Impact of preexisiting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies. J Clin Oncol 1996; 14:3036–3042.PubMedGoogle Scholar
  73. 73.
    Alvarnas JC, Negrin RS, Horning SJ et al. High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant 2000; 6:352–358.CrossRefPubMedGoogle Scholar
  74. 74.
    Neuwelt EA, Goldman DL, Dahlborg SA et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 1991; 9:1580–1590.PubMedGoogle Scholar
  75. 75.
    McAllister LD, Doolittle ND, Guastadisegni PE et al. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 2000; 46: 51–61.CrossRefPubMedGoogle Scholar
  76. 76.
    Kraemer DF, Fortin D, Doolittle ND et al. Association of total dose intensity of chemotherapy in primary central nervous system lymphoma (human non-acquired immunodeficiency syndrome) and survival. Neurosurgery 2001; 48:1033–1041.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Nancy D. Doolittle
    • 1
  1. 1.Department of NeurologyOregon Health & Science UniversityPortlandUSA

Personalised recommendations